
SpringWorks Therapeutics SWTX
Quartalsbericht 2025-Q1
hinzugefügt 09.05.2025
SpringWorks Therapeutics Langfristige Verbindlichkeiten 2011-2026 | SWTX
Langfristige Verbindlichkeiten Jährlich SpringWorks Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 789 K | 64.1 M | 12.6 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 64.1 M | 789 K | 25.8 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.5 | 0.45 % | $ 862 M | ||
|
ADC Therapeutics SA
ADCT
|
378 M | $ 3.83 | 1.32 % | $ 105 M | ||
|
Agenus
AGEN
|
264 M | $ 3.64 | 9.31 % | $ 108 M | ||
|
Agios Pharmaceuticals
AGIO
|
157 M | $ 35.08 | -0.36 % | $ 2.03 B | ||
|
Akebia Therapeutics
AKBA
|
168 M | $ 1.39 | 0.36 % | $ 357 M | ||
|
Akari Therapeutics, Plc
AKTX
|
50 K | $ 3.95 | -11.63 % | $ 266 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Aldeyra Therapeutics
ALDX
|
11.4 M | $ 1.57 | -5.42 % | $ 94.3 M | ||
|
Aligos Therapeutics
ALGS
|
15 M | $ 8.08 | 1.38 % | $ 79.9 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 331.14 | 3.85 % | $ 43.4 B | ||
|
Altimmune
ALT
|
4.4 M | $ 3.4 | 1.8 % | $ 300 M | ||
|
ALX Oncology Holdings
ALXO
|
5.97 M | $ 1.99 | 0.81 % | $ 107 M | ||
|
Amgen
AMGN
|
37.2 B | $ 344.03 | -1.12 % | $ 185 B | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Amneal Pharmaceuticals
AMRX
|
2.79 B | $ 12.27 | -1.68 % | $ 3.85 B | ||
|
Anika Therapeutics
ANIK
|
26.1 M | $ 14.99 | 1.28 % | $ 220 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
ANI Pharmaceuticals
ANIP
|
182 M | $ 73.8 | -0.55 % | $ 1.43 B | ||
|
Annexon
ANNX
|
1.05 M | $ 5.56 | 1.0 % | $ 862 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Aptorum Group Limited
APM
|
2.21 M | $ 0.88 | -5.16 % | $ 4.8 M | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Aprea Therapeutics
APRE
|
303 K | $ 0.7 | -1.87 % | $ 4.58 M | ||
|
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.12 | -0.24 % | $ 441 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
30.4 M | $ 8.14 | 1.31 % | $ 223 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Ardelyx
ARDX
|
50.9 M | $ 5.99 | 0.84 % | $ 1.44 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
argenx SE
ARGX
|
226 M | $ 749.99 | 0.48 % | $ 25 B | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Arcutis Biotherapeutics
ARQT
|
167 M | $ 24.06 | 1.82 % | $ 3.06 B | ||
|
Arvinas
ARVN
|
42.1 M | $ 10.87 | 0.14 % | $ 771 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
686 M | $ 60.28 | -1.23 % | $ 8.06 B | ||
|
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | ||
|
Assembly Biosciences
ASMB
|
18.2 M | $ 29.51 | 1.72 % | $ 331 M | ||
|
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.62 | 1.82 % | $ 8.71 B |